There are currently 23 ongoing clinical trials involving Eosinophilic Esophagitis
Of the 23 trials,8 trials are in Phase II
Furthermore, 8 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Eosinophilic Esophagitis, a Gastrointestinal indication. The highest number of ongoing clinical trials involving Eosinophilic Esophagitis is in North America. Europe and Asia-Pacific are among some of the other prominent regions involved in Eosinophilic Esophagitis-related drug trials.
Ellodi Pharmaceuticals: The leading ongoing Eosinophilic Esophagitis-related clinical trials sponsor
Ellodi Pharmaceuticals, the United States of America-based pharmaceutical company, is the top sponsor for Eosinophilic Esophagitis-related ongoing clinical trials.
Regeneron Pharmaceuticals Inc, Celgene Corp, Allakos Inc, Bristol-Myers Squibb Co, Mayo Clinic, and Indiana University are a few other notable sponsors involving Eosinophilic Esophagitis.
A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Eosinophilic Esophagitis
Budesonide (Jorveza) is the sole marketed drug involving Eosinophilic Esophagitis.
Budesonide (Jorveza), a Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist, is indicated for the treatment of eosinophilic esophagitis (EOE) in adults (older than 18 years of age). The drug is marketed globally including in the UK, France, Germany, and Australia by several prominent pharma giants including Dr. Falk Pharma GmbH. Budesonide was first approved in 2018 and formulated as dispersible tablets for the oral route of administration.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer